Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

BACKGROUND: National payers across Europe have been increasingly looking into innovative reimbursement approaches – called managed entry agreements (MEAs) – to balance the need to provide rapid access to potentially beneficial orphan medicinal products (OMPs) with the requirements to circumscribe un...

Descripción completa

Detalles Bibliográficos
Autores principales: Morel, Thomas, Arickx, Francis, Befrits, Gustaf, Siviero, Paolo, van der Meijden, Caroline, Xoxi, Entela, Simoens, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882782/
https://www.ncbi.nlm.nih.gov/pubmed/24365263
http://dx.doi.org/10.1186/1750-1172-8-198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882782/
https://www.ncbi.nlm.nih.gov/pubmed/24365263
http://dx.doi.org/10.1186/1750-1172-8-198

Ejemplares similares